S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
NASDAQ:CCCC

C4 Therapeutics Stock Forecast, Price & News

$23.40
-1.04 (-4.26%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$23.00
▼
$24.80
50-Day Range
$23.40
▼
$41.70
52-Week Range
$23.00
▼
$51.21
Volume
542,567 shs
Average Volume
403,636 shs
Market Capitalization
$1.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.73
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive CCCC News and Ratings via Email

Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


C4 Therapeutics logo

About C4 Therapeutics

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Headlines

C4 Therapeutics (NASDAQ:CCCC) Hits New 1-Year Low at $24.25
January 20, 2022 |  americanbankingnews.com
C4 Therapeutics (NASDAQ:CCCC) Stock Price Down 7.7%
January 18, 2022 |  americanbankingnews.com
C4 Therapeutics (NASDAQ:CCCC) Hits New 1-Year Low at $26.23
January 14, 2022 |  americanbankingnews.com
Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy?
January 12, 2022 |  finance.yahoo.com
C4 Therapeutics (NASDAQ:CCCC) Shares Up 7%
January 10, 2022 |  americanbankingnews.com
C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio
January 10, 2022 |  finance.yahoo.com
C4 Therapeutics (NASDAQ:CCCC) Reaches New 1-Year Low at $27.81
January 7, 2022 |  americanbankingnews.com
C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022 |  finance.yahoo.com
What Makes C4 Therapeutics, Inc. (CCCC) a New Buy Stock
December 29, 2021 |  finance.yahoo.com
C4 Therapeutics (NASDAQ:CCCC) Trading 3.7% Higher
December 28, 2021 |  americanbankingnews.com
C4 Therapeutics Added to NASDAQ Biotechnology Index
December 17, 2021 |  finance.yahoo.com
C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind the Upgrade
November 22, 2021 |  msn.com
Why C4 Therapeutics (CCCC) Might Surprise This Earnings Season
November 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CCCC
Previous Symbol
CUSIP
N/A
CIK
1662579
Web
www.c4therapeutics.com
Phone
617-231-0700
Fax
N/A
Employees
99
Year Founded
N/A

Sales & Book Value

Annual Sales
$33.19 million
Price / Sales
34.28
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.53 per share
Price / Book
3.58

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
$-66.33 million
Net Margins
-265.03%
Pretax Margin
-265.40%
Return on Equity
-26.49%
Return on Assets
-19.89%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
8.47
Quick Ratio
8.47

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
48,626,000
Free Float
38,395,000
Market Cap
$1.14 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/21/2022
Next Earnings (Estimated)
3/10/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

2.28 out of 5 stars

Medical Sector

314th out of 1,418 stocks

Biological Products, Except Diagnostic Industry

47th out of 206 stocks

Analyst Opinion: 3.4Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -












C4 Therapeutics (NASDAQ:CCCC) Frequently Asked Questions

Is C4 Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" C4 Therapeutics stock.
View analyst ratings for C4 Therapeutics or view top-rated stocks.

When is C4 Therapeutics' next earnings date?

C4 Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for C4 Therapeutics.

How were C4 Therapeutics' earnings last quarter?

C4 Therapeutics, Inc. (NASDAQ:CCCC) issued its earnings results on Wednesday, November, 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06. The company had revenue of $8.50 million for the quarter, compared to analyst estimates of $7.28 million. C4 Therapeutics had a negative trailing twelve-month return on equity of 26.49% and a negative net margin of 265.03%.
View C4 Therapeutics' earnings history.

What price target have analysts set for CCCC?

7 brokers have issued 12-month price targets for C4 Therapeutics' shares. Their forecasts range from $20.00 to $63.00. On average, they expect C4 Therapeutics' stock price to reach $48.50 in the next year. This suggests a possible upside of 107.3% from the stock's current price.
View analysts' price targets for C4 Therapeutics or view top-rated stocks among Wall Street analysts.

Who are C4 Therapeutics' key executives?

C4 Therapeutics' management team includes the following people:
  • Mr. Marc A. Cohen, Co-Founder, Exec. Chairman & Sec. (Age 58, Pay $69.5k)
  • Mr. Andrew J. Hirsch, CEO, Pres & Director (Age 50, Pay $607.96k)
  • Dr. Kenneth C. Anderson Ph.D., M.D., Co-Founder, Independent Director & Member of Scientific Advisory Board (Age 70, Pay $27.5k)
  • Mr. William T. McKee, Interim CFO & Treasurer (Age 59, Pay $1.07M)
  • Dr. Adam S. Crystal M.D., Ph.D., Chief Medical Officer (Age 44, Pay $661.55k)
  • Dr. Nathanael S. Gray Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Stewart Fisher, Chief Scientific Officer (Age 54) (LinkedIn Profile)
  • Ms. Kendra Adams, Sr. VP of Communications & Investor Relations
  • Ms. Jolie M. Siegel J.D., Chief Legal Officer (Age 44) (LinkedIn Profile)
  • Kristina Zambouras, Director of HR

When did C4 Therapeutics IPO?

(CCCC) raised $150 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

What is C4 Therapeutics' stock symbol?

C4 Therapeutics trades on the NASDAQ under the ticker symbol "CCCC."

How do I buy shares of C4 Therapeutics?

Shares of CCCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is C4 Therapeutics' stock price today?

One share of CCCC stock can currently be purchased for approximately $23.40.

How much money does C4 Therapeutics make?

C4 Therapeutics has a market capitalization of $1.14 billion and generates $33.19 million in revenue each year.

How many employees does C4 Therapeutics have?

C4 Therapeutics employs 99 workers across the globe.

What is C4 Therapeutics' official website?

The official website for C4 Therapeutics is www.c4therapeutics.com.

How can I contact C4 Therapeutics?

The company can be reached via phone at 617-231-0700 or via email at [email protected].


This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.